Delcath Systems Inc (DCTH)

4.12
0.20 5.10
NASDAQ : Health Care
Prev Close 3.92
Open 3.92
Day Low/High 3.86 / 4.33
52 Wk Low/High 3.35 / 10.88
Volume 111.95K
Avg Volume 29.50K
Exchange NASDAQ
Shares Outstanding 1.51M
Market Cap 4.58M
EPS -14.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

European Data Supporting Survival Benefit With Delcath's CHEMOSAT System Presented At 6th European Post-Chicago Melanoma/Skin Cancer Meeting

European Data Supporting Survival Benefit With Delcath's CHEMOSAT System Presented At 6th European Post-Chicago Melanoma/Skin Cancer Meeting

Unprecedented Progression Free and Overall Survival Observed in University Hospital Southampton Retrospective Analysis

Delcath European Patient Education Website Receives Prestigious Digital Health Award

Delcath European Patient Education Website Receives Prestigious Digital Health Award

Againsttheodds.eu Recognized for High Quality Consumer Health Content

Delcath Announces First CHEMOSAT® Procedures In Turkey

Delcath Announces First CHEMOSAT® Procedures In Turkey

Growing Adoption of CHEMOSAT Permits Expansion Outside of European Union

Delcath Announces Engagement Of Lars E. Birgerson, M.D., Ph. D As Global Medical Consultant

Delcath Announces Engagement Of Lars E. Birgerson, M.D., Ph. D As Global Medical Consultant

Distinguished Physician and Pharmaceutical Industry Executive to Serve as Senior Advisor for Clinical Development

Delcath Announces Initiation Of Phase 3 Trial Of Melphalan/HDS System For Treatment Of Hepatic Dominant Ocular Melanoma

Delcath Announces Initiation Of Phase 3 Trial Of Melphalan/HDS System For Treatment Of Hepatic Dominant Ocular Melanoma

Moffitt Cancer Center Begins Patient Enrollment in FOCUS Trial; Study Results to Support U.S. New Drug Application

Delcath Announces Special Protocol Assessment Agreement With FDA For New Phase 3 Trial In Hepatic Dominant Ocular Melanoma

Delcath Announces Special Protocol Assessment Agreement With FDA For New Phase 3 Trial In Hepatic Dominant Ocular Melanoma

Agreement Provides Regulatory Pathway for Melphalan/HDS with a Single Phase 3 Trial; Satisfies Substantial Number of Requirements in FDA's September 2013 Complete Response Letter

Review Of Delcath Melphalan/HDS System Published In

Review Of Delcath Melphalan/HDS System Published In "Cardiovascular & Interventional Radiology"

First Review of Current Product and Procedure to be used in the Planned Global Phase 3 Trial

Delcath Announces CHEMOSAT Treatment Milestones In Europe

Delcath Announces CHEMOSAT Treatment Milestones In Europe

250th Treatment Performed Since Introduction of Second Generation CHEMOSAT in Europe; Prestigious Harley Street Clinic Activated in the United Kingdom

Data Supporting Delcath's CHEMOSAT System Presented At The European Association Of Dermato Oncology Annual Congress

Data Supporting Delcath's CHEMOSAT System Presented At The European Association Of Dermato Oncology Annual Congress

Three European Studies Report on Use of CHEMOSAT for Liver Metastases from Ocular/Uveal Melanoma

Delcath Announces National Reimbursement Coverage For CHEMOSAT Procedures In Germany

Delcath Announces National Reimbursement Coverage For CHEMOSAT Procedures In Germany

German Authority Establishes Procedure Code for CHEMOSAT; ZE Code is First National Reimbursement Mechanism for CHEMOSAT in Europe

Data Supporting Delcath's Chemosat System Presented At The Cardiovascular And Interventional Radiology Society Annual Meeting

Data Supporting Delcath's Chemosat System Presented At The Cardiovascular And Interventional Radiology Society Annual Meeting

Poster presentations present results of filter efficiency and safety and efficacy of CHEMOSAT treatment in patients with unresectable liver metastases

Retrospective Study Examining Delcath's CHEMOSAT And Isolated Hepatic Perfusion Presented At ECCO Annual Meeting

Retrospective Study Examining Delcath's CHEMOSAT And Isolated Hepatic Perfusion Presented At ECCO Annual Meeting

First of Several Abstracts on CHEMOSAT to be Presented at Major Medical Meetings in Autumn 2015